The clinical value of drug litigation
Executive Summary
Litigation against pharma companies can result in better definition of drug risks, Harvard University Medical School's Aaron Kesselheim and Jerry Avorn argue in a Jan. 17 JAMA article. In several cases involving SSRIs and COX-2s, lawsuits produced useful data that previously had not been publicly released, the authors say. Suits could also motivate "proper disclosure initially by presenting the possibility of substantial damages in cases of misconduct." Describing litigants as "drug safety researchers of last resort," the essay criticizes FDA's effort to pre-empt product liability claims (1"The Pink Sheet" Aug. 28, 2006, p. 7)...You may also be interested in...
Court Ruling On Preemption Leaves Window Open For False Advertising Suits
FDA's failure to include false advertising claims in its policy on preemption implies that the agency "does not intend its review of promotional materials to preempt false advertising claims," according to a recent federal court decision
QUOTED. 19 February 2020. Stephen Hahn.
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: